Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Curfman

Showing results (21-30 of 64) with videos related to

Pageof 7
Sort By:
JAMA Internal Medicine|May 23, 2017
Risks of Statin Therapy in Older AdultsGregory Curfman
JAMA|November 15, 2020
Do Omega-3 Fatty Acids Benefit Health?Gregory Curfman
JAMA|December 22, 2020
Digitalis Glycosides for Heart Rate Control in Atrial FibrillationGregory Curfman
JAMA Health Forum|October 11, 2022
United States v Google-Implications of the Antitrust Lawsuit for Health InformationGregory Curfman
JAMA|April 16, 2025
NIH Caps Indirect Cost RatesGregory Curfman
JAMA|February 20, 2019
Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid ProductsAmeet Sarpatwari, Gregory Curfman
JAMA Internal Medicine|February 27, 2018
The Trade-offs When Focusing on the Mortality BenefitAlbert Liu, Gregory Curfman
Nature Biotechnology|June 15, 2022
Vascepa patents under legal scrutinyGregory Curfman, Justin Cole
JAMA|November 3, 2020
Reconsidering Health Care Fraud and Abuse LawsCarmel Shachar, Gregory Curfman
Nature Biotechnology|December 8, 2022
The Humira patent thicket, the Noerr-Pennington doctrine and antitrust's patent problemRyan Knox, Gregory Curfman
Pageof 7

Showing results (21-30 of 64) with videos related to

Sort By:
Pageof 7
JAMA Internal Medicine|May 23, 2017
Risks of Statin Therapy in Older AdultsGregory Curfman
JAMA|November 15, 2020
Do Omega-3 Fatty Acids Benefit Health?Gregory Curfman
JAMA|December 22, 2020
Digitalis Glycosides for Heart Rate Control in Atrial FibrillationGregory Curfman
JAMA Health Forum|October 11, 2022
United States v Google-Implications of the Antitrust Lawsuit for Health InformationGregory Curfman
JAMA|April 16, 2025
NIH Caps Indirect Cost RatesGregory Curfman
JAMA|February 20, 2019
Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid ProductsAmeet Sarpatwari, Gregory Curfman
JAMA Internal Medicine|February 27, 2018
The Trade-offs When Focusing on the Mortality BenefitAlbert Liu, Gregory Curfman
Nature Biotechnology|June 15, 2022
Vascepa patents under legal scrutinyGregory Curfman, Justin Cole
JAMA|November 3, 2020
Reconsidering Health Care Fraud and Abuse LawsCarmel Shachar, Gregory Curfman
Nature Biotechnology|December 8, 2022
The Humira patent thicket, the Noerr-Pennington doctrine and antitrust's patent problemRyan Knox, Gregory Curfman
Pageof 7